Back to today’s briefing

Story perspectives

FDA Approves Breakthrough Gene Therapies for Rare Diseases

3/27/2025

46 7

Summary

Story summary

Sarepta Therapeutics’ Elevidys and Novartis’ Zolgensma have gained FDA approval, offering hope for those battling Duchenne muscular dystrophy and spinal muscular atrophy. At the 2025 MDA Conference, experts delved into the safety and ethical challenges of gene therapy. In exciting news, SineuGene's ALS therapy has also received FDA clearance, while Wave Life Sciences celebrated promising Phase II results for its DMD treatment.

1 of 1

Story summary

Sarepta Therapeutics’ Elevidys and Novartis’ Zolgensma have gained FDA approval, offering hope for those battling Duchenne muscular dystrophy and spinal muscular atrophy. At the 2025 MDA Conference, experts delved into the safety and ethical challenges of gene therapy. In exciting news, SineuGene's ALS therapy has also received FDA clearance, while Wave Life Sciences celebrated promising Phase II results for its DMD treatment.